$796 Million is the total value of MPM BioImpact LLC's 13 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 31.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | New | Cullinan Management, Inc. | $329,772,000 | – | 7,913,887 | +100.0% | 41.43% | – |
| HARP | Sell | Harpoon Therapeutics, Inc. | $81,555,000 | -37.0% | 3,898,422 | -50.0% | 10.25% | -8.4% |
| ITOS | Sell | iTeos Therapeutics, Inc. | $80,513,000 | -49.5% | 2,355,557 | -50.0% | 10.12% | -26.5% |
| TCRR | Sell | TCR2 Therapeutics, Inc. | $74,431,000 | -64.3% | 3,370,982 | -50.0% | 9.35% | -48.1% |
| RPTX | Sell | Repare Therapeutics, Inc. | $63,521,000 | -61.2% | 2,069,749 | -56.7% | 7.98% | -43.6% |
| Sell | MEI Pharma, Inc. | $34,773,000 | -35.0% | 10,137,859 | -50.0% | 4.37% | -5.5% | |
| ONCR | Sell | Oncorus, Inc. | $33,088,000 | -78.5% | 2,377,031 | -50.0% | 4.16% | -68.7% |
| TPTX | Sell | Turning Point Therapeutics, Inc. | $25,462,000 | -66.2% | 269,186 | -56.4% | 3.20% | -50.8% |
| GTHX | Sell | G1 Therapeutics, Inc. | $22,323,000 | -56.4% | 927,794 | -67.4% | 2.80% | -36.6% |
| EPZM | Sell | Epizyme, Inc. | $20,308,000 | -63.9% | 2,331,534 | -55.0% | 2.55% | -47.5% |
| MRUS | Sell | Merus N.V. | $14,641,000 | -40.4% | 700,879 | -50.0% | 1.84% | -13.3% |
| YMAB | Sell | YmAbs Therapeutics, Inc. | $10,200,000 | -69.5% | 337,291 | -50.0% | 1.28% | -55.5% |
| ADCT | Sell | ADC Therapeutics, Inc. | $5,322,000 | -84.6% | 218,027 | -79.8% | 0.67% | -77.6% |
| AUTL | Exit | Autolus Therapeutics Limited | $0 | – | -79,480 | -100.0% | -0.06% | – |
| BDTX | Exit | Black Diamond Therapeutcs, Inc. | $0 | – | -43,615 | -100.0% | -0.12% | – |
| AVRO | Exit | AVROBIO, Inc. | $0 | – | -364,285 | -100.0% | -0.44% | – |
| NTLA | Exit | Intellia Therapeutics, Inc. | $0 | – | -128,162 | -100.0% | -0.60% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.